Celltrion to challenge sanction over canceled diagnostic-kit contract
South Korea’s Fair Trade Commission has sanctioned Celltrion over its cancellation of a diagnostic-kit manufacturing contract, finding that the subcontractor was not responsible for the circumstances behind the cancellation, according to Yonhap. Celltrion plans to challenge the decision in an administrative lawsuit.
The contract dispute
The case turns on whether Celltrion had grounds to cancel work it had outsourced. The commission’s finding concerns the treatment of the subcontractor; Celltrion’s planned lawsuit will give the company a route to contest the sanction in court.
Financial context
Celltrion’s regulatory filing shows revenue rose +44.96% and operating profit rose +86.33% from Q2 2025 to Q2 2026. Its operating margin was 32.42% in Q2 2026. Those figures describe the company’s performance during the filed period; they do not establish the outcome of the contract dispute.
By the Numbers
| Metric | What it measures | Value | Period |
|---|---|---|---|
| Revenue (DART filing) — Celltrion, Inc. | Change from a year earlier (latest filed report) | +44.96% | Q2 2025 → Q2 2026 |
| Operating profit (DART filing) — Celltrion, Inc. | Change from a year earlier (latest filed report) | +86.33% | Q2 2025 → Q2 2026 |
| Operating margin (DART filing) — Celltrion, Inc. | Operating profit ÷ revenue (latest filed report) | 32.42% | Q2 2026 |
Sources (7) — Yonhap News Agency · DART (Financial Supervisory Service)
- Yonhap News Agency, 2026-10-29
- Yonhap News Agency, 2026-10-29
- DART (Financial Supervisory Service), 2026-10-30
- DART (Financial Supervisory Service), 2026-10-30
- DART (Financial Supervisory Service), 2026-10-30
- DART (Financial Supervisory Service), 2026-10-30
- DART (Financial Supervisory Service), 2026-10-30
출처: 금융감독원 전자공시시스템(DART)
This article is for informational purposes only and is not investment advice. Figures reflect the period stated and may differ from current values. You are responsible for your own investment decisions.